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Cancer screening is a major healthcare issue. Screening modalities
are constantly changing due to improvements in technology. For
example, low-dose computed tomography (CT) has a greater like-
lihood of detecting lung cancer at an earlier and potentially more
curable stage than does conventional chest radiography (Kaneko 
et al, 1996; Henschke et al, 1999). In breast cancer screening,
mammography or ultrasonography is now used instead of just
palpation. Studies of several other modalities are underway to
elucidate their effectiveness (Kramer et al, 1994). 
Positron emission tomography (PET) with 18F-fluorodeoxy-
glucose (FDG) has been developed to quantitatively assess local
glucose metabolism. Because malignant tumours exhibit increased
glucose metabolism, quantification of FDG uptake by PET helps
to differentiate between benign and malignant tumours (Rigo et al,
1996), to determine the degree of malignancy (Adler et al, 1991),
to evaluate the effectiveness of chemotherapy or radiotherapy
(Price and Jones, 1995) and to predict prognosis (Okada et al,
1994; Nakata et al, 1997; Oshida et al, 1998). Since the invention
of the whole-body imaging technique (Guerrero et al, 1990), PET
has also been used to depict hypermetabolic cancers. PET imaging
has been shown to be sensitive enough to detect various cancers
including lung, breast, colorectal, pancreatic and head and neck
cancer, and malignant lymphoma and melanoma (Conti et al,
1996; Rigo et al, 1996; Delbeke, 1999). It can also be used
successfully in patients with unknown primary tumour (Lassen 
et al, 1999). Thus PET imaging has the potential to detect cancers
of many types at early stages with a single study. 
Our facility has 3 whole-body PET scanners, and we have
begun to use them in addition to conventional modalities for
cancer screening (Yasuda and Shohtsu, 1997). In this study, we
analysed whether PET imaging is reliably applicable to cancer
screening in asymptomatic individuals. 
SUBJECTS AND METHODS 
Our institution is a membership-based medical club offering
periodic health checks to members. Subjects of this study were
club members. As part of our cancer screening programme, whole-
body PET scanning was performed in conjunction with conven-
tional modalities between September 1994 and March 1999: chest
radiography and spiral CT scan for lung cancer; physical examina-
tion and ultrasonography (beginning January 1996) for breast
cancer; immunochemical faecal occult-blood test for colorectal
cancer; digital examination and serum prostate-specific antigen
(PSA) measurement for prostatic cancer; and ultrasonography for
thyroid (beginning January 1996), liver and renal cancers. During
this period, 3165 asymptomatic club members (2017 men and
1148 women; ages 52.2 ± 10.4 years, mean ± SD) underwent
cancer screening including PET for a total of 5575 examinations.
All participants fasted for at least 4 h before PET studies. 45 to
60 min after the administration of 260 to 370 MBq FDG, emission
scanning was performed with an ECAT EXACT 47 whole-body
PET scanner (Siemens/CTI, Knoxville, TN, USA). Images were
obtained from the pelvis to the maxilla for 7 min at each bed
position. Transmission scanning for attenuation correction was not
carried out. Grey-scale hard copy images of transaxial slices were
printed and interpreted visually by one physician (SY). Images of
coronal and sagittal slices were also available. The criterion for a
positive PET finding was a visible, focally-increased FDG uptake
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recognized benign lesions (Engel et al, 1996; Rigo et al, 1996).
Results of simultaneously performed conventional examinations
were also available. When abnormal findings were noted by
conventional examination, the participant was, as a rule, referred
to a local hospital for follow-up or further examination. Follow-up
periods were no less than 10 months. Follow-up information was
obtained directly from study subjects or their doctors, and cancers
discovered within 1 year after screening were documented for
analysis. Our screening protocols were approved by an independ-
ent ethics committee, and informed consent was obtained from
each study participant. 
RESULTS 
Among our 3165 asymptomatic participants, malignant tumours
were identified in 67 (2.1%) within 1 year after screening. PET
findings were true-positive in 36 of these cancers (Table 1). Most
of the 36 patients underwent successful surgical treatment. 8 of 10
lung cancers were characterized as stage I tumours (T1, tumour 
3 cm or less in the greatest dimension; N0, no regional lymph 
node metastasis; M0, no distant metastasis) (Sobin and Wittekind,
1997). An example PET scan of one such case is shown in Figure 1.
8 participants were found to have thyroid cancer and underwent
surgery. Histopathologically, these tumours were determined to be
papillary adenocarcinomas, and microscopic lymph node meta-
stasis was observed in 3 patients. The smallest was a nonpalpable
6-mm tumour in which microscopic nodal metastasis was
observed in 5 of 37 dissected lymph nodes. 5 patients with breast
cancer including the nonpalpable 6-mm cancer underwent poten-
tially curative surgery. The 6-mm breast cancer was not visible on
a mammogram obtained later at the patient’s local hospital
(Yasuda et al, 1999). 4 participants were found to have colorectal
cancer and underwent potentially curative surgery. An ovarian
cancer and a parapharyngeal cancer (adenoid cystic carcinoma)
were included among the remaining 9 PET-positive cancers. Both
patients also underwent potentially curative surgery. 4 participants
were found to have colonic adenoma with carcinoma in situ and
were not counted among the 36 cases. 
31 cancers were PET-negative. 22 of these were detected by the
conventional examinations performed during the screening (Table 2),
and 9 were discovered within 1 year through examinations
obtained mainly because of clinical symptoms (Table 3). 14 of
these cancers (45%) were of urologic origin. 6 hepatomas, all
smaller than or equal to 2 cm in diameter, in 5 participants were
false-negative with PET but positive with ultrasonography. Three
small cell lung cancers were false-negative with PET: an 8-mm
tubular adenocarcinoma and 1.1- and 1.5-cm bronchioloalveolar
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Table 1 PET-positive cancers 
Patient  Age Sex Diagnosis Tumour size (cm) Lymph node metastasis Treatment Conventional imaging with 
no. positive findings 
1 66 M Lung cancer 1.0 – Surgery – 
2 49 M Lung cancer 1.3 – Surgery CT 
3 55 F Lung cancer 1.3 – Surgery CT 
4 66 M Lung cancer 1.5 – Surgery CT 
5 55 F Lung cancer 1.9 – Surgery CR, CT 
6 65 M Lung cancer 2.4 – Surgery CR, CT 
7 77 F Lung cancer 2.7 – Surgery CR, CT 
8 47 M Lung cancer 2.9 – Surgery CR, CT 
9 67 M Lung cancer 3.6 – Surgery CT 
10 70 M Lung cancer (Stage III) (+) Radiation CR, CT 
11 39 F Thyroid cancer 0.6 + Surgery  – 
12 48 F Thyroid cancer 1.0 – Surgery  US 
13 56 F Thyroid cancer 1.0 + Surgery  US 
14 39 M Thyroid cancer 1.1 + Surgery  US 
15 57 M Thyroid cancer 1.1 – Surgery  US 
16 34 M Thyroid cancer 1.2 – Surgery  US 
17 50 F Thyroid cancer 1.4 – Surgery  US 
18 48 M Thyroid cancer 3.0 – Surgery  US 
19 43 F Breast cancer 0.6 – Surgery  – 
20 48 F Breast cancer 1.3 – Surgery  US 
21 44 F Breast cancer 1.8 + Surgery  US 
22 61 F Breast cancer 2.0 – Surgery  US 
23 51 F Breast cancer 2.4 + Surgery  US 
24 73 M Colon cancer 3.4 + Surgery  – 
25 45 M Colon cancer 3.5 – Surgery  – 
26 53 M Rectal cancer 4.0 – Surgery  – 
27 40 F Colon cancer 6.0 – Surgery  – 
28 60 M Lymphoma (thyroid) 6.0 – Chemo. + Rad. US 
29 52 F Lymphoma NE NE Chemotherapy – 
30 67 F Hepatoma NE + No treatment  US 
31 76 M Metastatic liver cancer 1.5 NE  Ethanol injection US 
32 64 M Parapharyngeal cancer 4.4 – Surgery – 
33 36 M Gastric cancer 3.5 – Surgery  US 
34 65 M Renal cancer 4.0 – Surgery  US 
35 71 F Ovarian cancer NE NE Surgery  US 
36 70 M Chronic myelogenous leukaemia NE NE Chemotherapy – 
CR = chest radiography; CT = computed tomography; US = ultrasonography: NE = not evaluated.adenocarcinomas. These were also negative with chest radio-
graphy but positive with spiral CT. One scirrhous-type breast
cancer (stage I, 1.5 cm) was false-negative with PET, though the
tumour was palpable and morphologically suspect for malignancy
with ultrasonography. 
Five participants underwent subsequent surgery due to false-
positive interpretation of PET findings. In the early period of this
study, we encountered one participant with chronic thyroiditis
mimicking a thyroid tumour. Ultrasonographic diagnosis at a local
hospital was also of thyroid tumour, and surgery was performed at
the hospital. Three participants with benign pulmonary lesions 
(a 1-cm tuberculoma and two 1-cm organized pneumonias) in
whom PET and CT were inconclusive underwent thoracoscopic
biopsy (2 cases) or thoracotomy (1 case) for definite diagnoses.
One participant was ultimately diagnosed with plasmacyte-rich
chronic maxillary sinusitis and underwent surgery at a local
hospital (Yasuda et al, 1998). 
DISCUSSION 
The ultimate goal of cancer screening is to detect curable cancers
that would be fatal if left untreated. However, the biology and
natural course of cancers are not fully understood (Hulka, 1998),
and the practical goal is reduced mortality. In this respect, the
effectiveness of cancer screening has been confirmed with the
faecal occult blood test for colorectal cancer (Hardcastle et al,
1996) and mammography for breast cancer in women in their fifth
decade (Taubes, 1997). A recent study showed CT to be better than
chest radiography for detecting lung cancer (Henschke et al,
1999). Several studies are underway to determine the efficacy of
screening for prostate cancer, lung cancer and ovarian cancer
(Kramer et al, 1994). These mass screenings target a single organ
and do not target low-prevalence cancers. This is due to the lack of
a proper modality and cost–benefit considerations. 
Whole-body PET imaging can be used to survey the entire
body; it is not confined to single organs. In our study, cancers of
many organs were positive with PET and were at potentially
curable stages. 8 of the 10 PET-positive lung cancers were stage I.
The remaining 2 were detected by PET 20 and 23 months prior to
final diagnosis at local hospitals. All subjects with PET-positive
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Figure 1 Lung cancer. On coronal tomographic PET images, high FDG
uptake was observed in the left upper lobe of the lung (arrow). Surgery was
performed. Histopathologically, the lesion was a 2.4 cm small cell carcinoma.
Lymph node metastasis was not observed.
Table 2 Cancers detected by conventional examinations 
Patient no. Age Sex Diagnosis Clinical stage or tumour size (cm) Methods of detection 
1 69 M Prostatic cancer Stage A2 DRE 
2 52 M Prostatic cancer (Stage B) PSA 
3 66 M Prostatic cancer Stage B PSA 
4 67 M Prostatic cancer Stage B PSA 
5 76 M Prostatic cancer Stage B PSA 
6 80 M Prostatic cancer Stage B PSA 
7 67 M Prostatic cancer Stage C PSA 
8 78 M Prostatic cancer Stage D PSA 
9 41 F Hepatoma 1.5 US 
10 48 M Hepatoma 1.5 US 
11 66 M Hepatoma 1.6 US 
12 71 F Hepatoma 1.0, 2.0 US 
13 41 M Renal cancer 1.5 US 
14 54 M Renal cancer 6.0 US 
15 46 F Renal cancer 8.5 US 
16 47 F Lung cancer 0.8 CT 
17 51 F Lung cancer 1.1 CT 
18 60 M Lung cancer 1.5 CT 
19 70 M Bladder cancer 3.0 US 
20 64 M Bladder cancer 1.5 US 
21 53 F Breast cancer 1.5 PE, US 
22 46 F Gastric cancer 4.0 US 
DRE = digital rectal examination; PSA = prostate-specific antigen; US = ultrasonography; CT = computerized tomography; PE =
physical examination. thyroid, breast or colorectal cancer underwent potentially curative
surgery. Furthermore, cancers were found that may have been
missed by conventional screening methods (such as the 6-mm
breast cancer, the 6-mm thyroid cancer, the 1-cm lung cancer and a
parapharyngeal cancer). 
In our study of asymptomatic individuals, various PET-negative
cancers were noted. These can be categorized into 4 groups:
urologic cancers, cancers of low cell density (signet ring cell
cancer of the stomach and scirrhous-type breast cancer), small
cancers and hypometabolic or FDG-negative cancers (lung cancer
and hepatoma). Renal excretion of FDG may hamper the detection
of urologic cancers (Miraldi et al, 1998). Low tumour cellularity
may result in low FDG accumulation (Higashi et al, 1998). The
spacial resolution of the PET machine is approximately 6 mm, 
and in tumours smaller than twice the resolution, partial-volume
effects decrease the sensitivity. As for hypometabolic cancers, it is
not known if cancers associated with hypometabolism are bio-
logically less aggressive or more indolent than those associated
with hypermetabolism. Some of these limitations have been men-
tioned in previous studies and should be kept in mind when using
PET for cancer detection. 
In our study, there were a few cases of gastric cancer, one of the
most prevalent cancers in Japan. In our country, gastric cancer
screening is common, and many of our subjects had undergone
stomach examinations at other institutions. In addition, quite a 
few participants were found to have thyroid cancer, which is not
addressed in conventional screening. 
One of the major issues of cancer screening is the balance
between cost and benefit. PET examination does involve substan-
tial cost compared to other examinations. In terms of cost–
benefit, no strong evidence has been obtained favouring the use of
PET for oncology patients except with respect to lung cancer
(Robert and Milne, 1999). Consequently, there is no convincing
rationale for the use of public funds to support PET screening of
the general population. In our institution, each member pays the
cost. In the future, if PET screening is deemed useful for properly-
selected, high-risk groups, debates around cost–benefit issues 
may arise. Radiation exposure risks heritable effects and carcino-
genesis (Hall, 1994). Heritable effects are, however, unlikely to
occur when the screening is applied to individuals beyond their
reproductive years. Radiation absorbed doses have been measured
in PET studies, and the effective dose equivalent was estimated 
at 2.4 × 10–2 mSv/MBq although an overestimation might have
occurred in the calculation (Mejia et al, 1991). We used 260 MBq
FDG. Therefore, the value is 6.24 mSv, which is lower than the 
7.6 mSv value with spiral CT of the chest (Nishizawa et al, 1995).
Our actual value was much lower than the calculated value.
Previous studies showed that the bladder is the organ receiving the
highest doses, and the absorbed dose to the bladder can be reduced
if subjects void at the proper time (Jones et al, 1982; Mejia et al,
1991). Our subjects were instructed to void between 45 and 60 min
after the administration of FDG. There is the prospect of further
reducing the absorbed dose considerably using 3D data aquisition,
with which the amount of FDG used is reduced by one-half. 
Hypermetabolism is not specific to cancer. Rigo et al (1996)
mentioned in their excellent review that FDG PET is not suited to
nonselective screening because of the likelihood of false-positives.
Our study is the first to deal with a large number of asymptomatic
persons. To avoid false-positive interpretations, we took into
account the fact that high FDG uptake is observed in some non-
malignant lesions. For example, we noticed in the early phase of
this study that diffuse thyroidal FDG uptake was a sign of subclin-
ical chronic thyroiditis (Yasuda et al, 1998). False-positive inter-
pretations that lead to unnecessary biopsy or surgery can be largely
avoided if the potential sites and characteristics of nonmalignant
lesions are recognized in the interpretation of the PET images.
Because one of the disadvantages of cancer screening is false-
positive results that demand further unnecessary examination,
our study results need to be further analysed with regard to false-
positive interpretations. 
Limitations of this study include the fact that there may be
cancers that were missed by the screening and were not discovered
within 1 year after screening. In this respect, both the follow-up
periods and the examinations conducted are not sufficient to
confirm the true incidence of cancers. Another limitation is that
our screening was not conducted by PET only. Conventional
examinations were performed simultaneously, and the results were
available during interpretion of the PET images. 
From our data, we believe that PET imaging has the potential 
to detect a wide variety of cancers at potentially curable stages in
asymptomatic individuals, provided the data is analysed by onco-
logists or radiologists who are experienced in the interpretation of
PET images. However, FDG PET imaging has obvious limitations
in the detection of urologic cancers, cancers of low cell dens-
ity, small cancers and hypometabolic or FDG-negative cancers.
Because PET examination does involve substantial cost, FDG
PET imaging is not suited to screening test of unselected general
population. We expect PET screening to be used in properly-
selected, high-risk groups in the future. 
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Table 3 Cancers missed by screening 
Patient no. Age Sex Diagnosis Clinical stage or tumour size (cm) Period after screening (months) 
1 45 M Gastric cancer Stage I, 7.0 2 
2 44 M Hepatoma 1.5 3 
3 77 F Gastric cancer Stage II, 4.0 4 
4 77 M Bladder cancer 1.0 5 
5 66 M Bile duct cancer 2.0 7 
6 68 M Gastric cancer (Limited in the mucosa) 7 
7 53 F Cervical cancer 1.5 8 
8 56 M Oesophageal cancer (Limited in the mucosa) 9 
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